Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial
This US multicentre study (n=157) found ruxolitinib cream was superior to placebo at doses of 1.5% BD and 1.5% OD (achievement of ≥50% improvement from baseline in facial Vitiligo Area Scoring Index at week 24 reported by 45% and 50%, respectively, vs 3% vehicle).
Source:
The Lancet
SPS commentary:
A related commentary discusses the results of this study and notes that further studies are needed to determine the rate of response to ruxolitinib in relation to disease duration and the combined effects with phototherapy. Comparative studies against topical steroids and calcineurin inhibitors would also help clinicians to position it against currently available therapeutic options. The observed side-effect of acne, which had a clear dose effect, needs close follow-up in Phase III studies.